Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

NCT03121534 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03121534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03121534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
June 22, 2017
Completion date
February 11, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic/lymphoid cancer, richter's transformation